Get the Stockscreener App
52.31
5.08%
-2.80
After Hours:
53.12
0.81
+1.55%
Jyong Biotech Ltd stock is traded at $52.31, with a volume of 134.37K.
It is down -5.08% in the last 24 hours and up +80.82% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$55.11
Open:
$54
24h Volume:
134.37K
Relative Volume:
2.07
Market Cap:
$3.98B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.56%
1M Performance:
+80.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$51.58
$56.50
1-Week Range:
$47.74
$61.00
52-Week Range:
$9.95
$61.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
52.31 | 4.19B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpWhat's Next? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Hits New 12-Month HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%What's Next? - MarketBeat
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat
Jyong Biotech Ltd. shares rise 6.64% intraday as SK Hynix reports Q2 2025 earnings. - AInvest
Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq
Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire
Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech
Jyong Biotech shares rise 3.85% in premarket after rating upgrade and CEO's Nasdaq bell ringing. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech Ltd. Rings the Closing Bell - Nasdaq
Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest
Taiwan’s Jyong Biotech doubles in value on Nasdaq debut - Investing.com
Taiwan's Jyong Biotech Makes Nasdaq Debut: $20M IPO Targets Breakthrough in Urinary Disease Treatment - Stock Titan
Amy Krambeck, MD, on innovation and building strong programs in endourology - Urology Times
Amy E. Krambeck, MD, on patient selection for HoLEP - Urology Times
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Expert on Aquablation’s comparable long-term outcomes in prostates of different sizes - Urology Times
Ravi Munver, MD, discusses the versatility of Aquablation treatment for BPH - Urology Times
Dr. Das on his experience with HoLEP for treating BPH - Urology Times
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
Study assesses Rezum therapy in large prostates - Urology Times
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Dr. Elterman on the new wave of BPH stents - Urology Times
Dr. Elterman on the future of stents for benign prostatic hyperplasia - Urology Times
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):